Erlotinib, Lung Neoplasms, Neoadjuvant Therapy
Conditions
Brief summary
This study propose neoadjuvant chemotherapeutic role by erlotinib.
Detailed description
It is widely accepted that patients with locally advanced non-small cell lung cancer would have better outcome with neoadjuvant therapy followed by surgery than surgery alone. However what should be the standard treatment option is still unclear. Erlotinib (Tarceva®)is an oral inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase and its anti-neoplastic effect is approved especially women, patients with adenocarcinoma, non-smoker and Asian population. Moreover if the malignant tissue has EGFR mutation, its efficacy is known to be enhanced. So we expect that in those population, patients with locally advanced, N2 positive, erlotinib would be more beneficial than conventional cytotoxic chemotherapy in safety and convenience as neoadjuvant therapy.
Interventions
DRUGErlotinib
Erlotinib 150mg per day for 8 weeks
Sponsors
Samsung Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Pathologically confirmed N2 positive and stage IIIA non-small cell lung cancer * Has more than 2 conditions out of following 3 conditions ; adenocarcinoma, non-smoker, women * Age ≥ 18 years and ECOG performance 0\ 1 * Has measurable lesion by RECIST 1.1 * No previous chemotherapy or radiation therapy * Adequate organ function by following; ANC ≥1,500/uL, hemoglobin ≥9.0g/dL, platelet ≥100,000/uL, PaO2 ≥ 60 mmHg, Serum Cr \< 1 x UNL or creatinine clearance \> 60 ml/min, Serum bilirubin \< 1 x UNL, AST (SGOT) and ALT (SGPT) \< 2.5 x UNL, alkaline phosphatase \< 5 x UNL * Written informed consent form
Exclusion criteria
* Pulmonary carcinoid tumor * Previous chemotherapy or radiation therapy * Previous history of malignancy within 5 years from study entry except treated non-melanomatous skin cancer or uterine cervical cancer in situ * Known allergic history of erlotinib * Interstitial lung disease or fibrosis on chest radiogram * Active infection, uncontrolled systemic disease (cardiopulmonary insufficiency, fatal arrhythmias, hepatitis) * Pregnant or nursing women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathologic down-staging | 36 months |
Secondary
| Measure | Time frame |
|---|---|
| Response rate | 36 months |
| Toxicity | 36 months |
| Progression free survival | 36 months |
| Overall survival | 36 months |
Countries
South Korea
Outcome results
None listed